Anaptysbio (ANAB) Total Non-Current Liabilities (2016 - 2026)

Anaptysbio has reported Total Non-Current Liabilities for 11 years, with the latest figure at $53.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 7.73% year-over-year to $53.2 million; the trailing twelve-month figure through Mar 2026 stood at $53.2 million (down 7.73% YoY), and the FY2025 full-year result was $50.7 million, down 14.92% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $53.2 million, up from $50.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $305.9 million in Q3 2022, with the low at $38.5 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $66.5 million across 5 years, with a median of $53.2 million in 2026.
• The largest YoY upside for Total Non-Current Liabilities was 52.06% in 2023 against a maximum downside of 81.8% in 2023.
• Anaptysbio's Total Non-Current Liabilities stood at $43.9 million in 2022, then advanced by 21.91% to $53.5 million in 2023, then climbed by 11.33% to $59.5 million in 2024, then fell by 14.92% to $50.7 million in 2025, then increased by 5.01% to $53.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $53.2 million (Q1 2026), $50.7 million (Q4 2025), and $50.7 million (Q3 2025), per Business Quant data.